Large-scale testing (Phase 3)Study completedNCT02282020
What this trial is testing
Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 266